{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T03:11:42Z","timestamp":1785553902260,"version":"3.56.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.ijrobp.2015.02.001","type":"journal-article","created":{"date-parts":[[2015,4,8]],"date-time":"2015-04-08T22:02:01Z","timestamp":1428530521000},"page":"67-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Management of Nodular Lymphocyte Predominant Hodgkin Lymphoma in the Modern Era"],"prefix":"10.1016","volume":"92","author":[{"given":"Martin T.","family":"King","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah S.","family":"Donaldson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasodha","family":"Natkunam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana H.","family":"Advani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Hoppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2015.02.001_bib1","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1038\/modpathol.2012.182","article-title":"Shades of gray between large B-cell lymphomas and Hodgkin lymphomas: Differential diagnosis and biological implications","volume":"26","author":"Harris","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ijrobp.2015.02.001_bib2","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1200\/JCO.2007.11.8869","article-title":"Lymphocyte-predominant and classical Hodgkin\u2019s Lymphoma: A comprehensive analysis from the German Hodgkin Study Group","volume":"26","author":"Nogov\u00e1","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.02.001_bib3","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJM198801283180404","article-title":"Nodular and diffuse types of lymphocyte predominance Hodgkin\u2019s disease","volume":"318","author":"Regula","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2015.02.001_bib4","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.2009.24.9516","article-title":"Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin\u2019s lymphoma","volume":"28","author":"Al-Mansour","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.02.001_bib5","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1200\/JCO.1999.17.3.776","article-title":"Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin\u2019s disease and lymphocyte-rich classical Hodgkin\u2019s disease: Report from the European Task Force on Lymphoma Project on lymphocyte-predominant Hodgkin\u2019s disease","volume":"17","author":"Diehl","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.02.001_bib6","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2009.24.0945","article-title":"Early-stage, lymphocyte-predominant Hodgkin\u2019s lymphoma: Patient outcomes from a large, single-institution series with long follow-up","volume":"28","author":"Chen","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.02.001_bib7","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/cncr.21303","article-title":"Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: A retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group","volume":"104","author":"Wirth","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2015.02.001_bib8","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1200\/JCO.2006.08.4772","article-title":"Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin\u2019s disease","volume":"25","author":"Donaldson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.02.001_bib9","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1001\/jama.2012.5847","article-title":"Association between radiotherapy vs no radiotherapy based on early response to vamp chemotherapy and survival among children with favorable-risk Hodgkin lymphoma","volume":"307","author":"Metzger","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2015.02.001_bib10","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1182\/blood-2011-06-361055","article-title":"Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group","volume":"118","author":"Eichenauer","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2015.02.001_bib11","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.2013.53.2069","article-title":"Mature results of a phase II study of rituximab therapy for nodular lymphocyte\u2013predominant Hodgkin lymphoma","volume":"32","author":"Advani","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.02.001_bib12","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/cncr.22762","article-title":"Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma: Experience from the European network group on pediatric Hodgkin lymphoma","volume":"110","author":"Mauz-K\u00f6rholz","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2015.02.001_bib13","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1080\/10428190600573291","article-title":"High relapse rate in children with non-advanced nodular lymphocyte predominant Hodgkin\u2019s lymphoma (NLPHL or nodular paragranuloma) treated with chemotherapy only","volume":"47","author":"Van Grotel","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ijrobp.2015.02.001_bib14","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1182\/blood-2011-07-365932","article-title":"Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome","volume":"118","author":"Savage","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2015.02.001_bib15","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1182\/blood-2004-02-0567","volume":"104","author":"Feugier","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2015.02.001_bib16","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.ijrobp.2008.09.049","article-title":"Low-dose involved-field radiotherapy as alternative treatment of nodular lymphocyte predominance Hodgkin\u2019s lymphoma","volume":"74","author":"Haas","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.02.001_bib17","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0167-8140(84)80001-8","article-title":"Lymphocyte predominant Hodgkin\u2019s disease: Clinical presentation and results of treatment","volume":"1","author":"Russell","year":"1984","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2015.02.001_bib18","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.ijrobp.2015.02.001_bib19","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1097\/00000478-200310000-00007","article-title":"Characterization of variant patterns of nodular lymphocyte predominant Hodgkin lymphoma with immunohistologic and clinical correlation","volume":"27","author":"Fan","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ijrobp.2015.02.001_bib20","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/bjh.12997","article-title":"Histopathological features and their prognostic impact in nodular lymphocyte-predominant Hodgkin lymphoma: A matched pair analysis from the German Hodgkin Study Group (GHSG)","volume":"167","author":"Hartmann","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ijrobp.2015.02.001_bib21","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2004.02.139","article-title":"Risk-adapted, combined-modality therapy with VAMP\/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin\u2019s disease","volume":"22","author":"Hudson","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.02.001_bib22","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1200\/JCO.20.3.630","article-title":"Stanford V and radiotherapy for locally extensive and advanced Hodgkin\u2019s disease: Mature results of a prospective clinical trial","volume":"20","author":"Horning","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.02.001_bib23","unstructured":"Reduced Duration Stanford V Chemotherapy With or Without Low-Dose Tailored-Field Radiation Therapy For Favorable Risk Pediatric Hodgkin Lymphoma - Full Text View. Available at: http:\/\/clinicaltrials.gov\/show\/NCT00846742. Accessed October 10,\u00a02014."},{"key":"10.1016\/j.ijrobp.2015.02.001_bib24","unstructured":"Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma - Full Text View. Available at: http:\/\/clinicaltrials.gov\/show\/NCT00352027. Accessed October 10,\u00a02014."},{"key":"10.1016\/j.ijrobp.2015.02.001_bib25","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1002\/pbc.24258","article-title":"Impact of low-dose involved-field radiation therapy on pediatric patients with lymphocyte-predominant Hodgkin lymphoma treated with chemotherapy: A report from the Children\u2019s Oncology Group","volume":"59","author":"Appel","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ijrobp.2015.02.001_bib26","doi-asserted-by":"crossref","unstructured":"Appel B, Chen L, Hutchison R, et al. Treatment of pediatric lymphocyte predominant Hodgkin lymphoma (LPHL): A report from the Children's Oncology Group. Klin P\u00e4diatr (Second International Symposium on Childhood, Adolescent, and Young Adult Hodgkin Lymphoma) 2014;226: O_10. http:\/\/dx.doi.org\/10.1055\/s-0034-1371120.","DOI":"10.1055\/s-0034-1371120"},{"key":"10.1016\/j.ijrobp.2015.02.001_bib27","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1200\/JCO.2000.18.3.498","article-title":"Risk of second malignancy after Hodgkin\u2019s disease in a collaborative British cohort: The relation to age at treatment","volume":"18","author":"Swerdlow","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.02.001_bib28","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1182\/blood-2013-12-541078","article-title":"Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis","volume":"123","author":"Xing","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2015.02.001_bib29","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.24819","article-title":"Nodular, lymphocyte-predominant Hodgkin lymphoma","volume":"116","author":"Biasoli","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2015.02.001_bib30","first-page":"2812","article-title":"Outcomes of nodular lymphocyte predominant Hodgkin\u2019s lymphoma (NLPHL) patients treated with R-CHOP","volume":"116","author":"Fanale","year":"2010","journal-title":"Blood (ASH Annu Meet Abstr)"},{"key":"10.1016\/j.ijrobp.2015.02.001_bib31","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1182\/blood-2013-07-515825","article-title":"The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group (GHSG)","volume":"122","author":"Hartmann","year":"2013","journal-title":"Blood"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301615001613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301615001613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T00:53:20Z","timestamp":1566521600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301615001613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0360301615001613"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2015.02.001","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Nodular Lymphocyte Predominant Hodgkin Lymphoma in the Modern Era","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2015.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}